Establishing cost-effectiveness of atypical neuroleptics.
Robert
G
G
Kennedy
P
P
D014150:Antipsychotic Agents / Q000191:economics*; D003362:Cost-Benefit Analysis; D006801:Humans; D013673:Technology Assessment, Biomedical
D014150:Antipsychotic Agents